Subject : : Survey to Assess the Prevalence & Management of Gastroesophageal Reflux Disease in Obstetrics & Gynecology Practice
GERD is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus. Gastroesophageal reflux disease (GERD) is as common in women as in men and may present with various symptoms, such as heartburn, regurgitation, dysphagia, or chest pain.
The prevalence of GERD in India ranges from 7.6% to 30%, being < 10% in most population studies, and higher in cohort studies. GERD is caused by multiple different mechanisms that can be intrinsic, structural, or both, leading to the disruption of the esophagogastric junction barrier resulting in exposure of the esophagus to acidic gastric contents.
Clinically, GERD typically manifests with symptoms of heartburn and regurgitation. It can also present in an atypical fashion with extra-esophageal symptoms such as chest pain, dental erosions, chronic cough, laryngitis, or asthma. Based on endoscopic and histopathologic appearance, GERD is classified into three different phenotypes: non-erosive reflux disease, erosive esophagitis, and Barrett's esophagus.
Over the years, the mainstay in the management of GERD has been lifestyle modifications and drugs like proton pump inhibitors & other antacids. However, medically refractory GERD is becoming increasingly common, requiring a tailored approach to the management of GERD.
This survey will help:
- To understand the demography of patients suffering from GERD/APD Gynecology & Obstetrics Practice in India
- To understand the disease profile, its diagnosis, and the use of various acid-neutralizing/suppressing medications in GERD/APD in Gynecology & Obstetrics Practice in India
- To understand the drug usage pattern of various acid-neutralizing/suppressing medications in the management of GERD/APD in Gynecology & Obstetrics Practice in India
- To understand the different approaches in the management of GERD/APD & Obstetrics Practice in India
If you agree to participate, you must provide an assessment response, to the standard questionnaire form. A link will be provided for the same on your registered email address.
We trust you and we are partners in safe and effective drug therapy. In that spirit, we hope you will consent to participate in this survey.
|